You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhenelzine
Accession NumberDB00780  (APRD00099)
TypeSmall Molecule
GroupsApproved
Description

An irreversible non-selective inhibitor of monoamine oxidase. May be used to treat major depressive disorder.

Structure
Thumb
Synonyms
Alazine
Fenelzina
Monofen
Nardil
Phenelzin
Phénelzine
Phenelzinum
β-Phenylethylhydrazine
External Identifiers
  • W 1544
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nardiltablet, film coated15 mg/1oralParke Davis Div Of Pfizer Inc1961-06-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Nardiltablet15 mgoralErfa Canada 2012 Inc1981-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Phenelzine Sulfatetablet, film coated15 mg/1oralGreenstone LLC1961-06-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenelzine Sulfatetablet15 mg/1oralNovel Laboratories, Inc.2011-02-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Phenelzine Sulfatetablet15 mg/1oralGolden State Medical Supply, Inc.2010-12-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Phenelzine Sulfatetablet15 mg/1oralGAVIS Pharmaceuticals, LLC2010-12-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
MargylDIM
NardelzinePfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Phenelzine Sulfate
ThumbNot applicableDBSALT000954
Phenelzine Sulphate
ThumbNot applicableDBSALT000955
Categories
CAS number51-71-8
WeightAverage: 136.1943
Monoisotopic: 136.100048394
Chemical FormulaC8H12N2
InChI KeyInChIKey=RMUCZJUITONUFY-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
IUPAC Name
(2-phenylethyl)hydrazine
SMILES
NNCCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenethylamines. These are compounds containing a phenethylamine moiety, which consists of a phenyl group substituted at the second position by an ethan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentPhenethylamines
Alternative Parents
Substituents
  • Phenethylamine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Hydrazine derivative
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of major depressive disorder. Has also been used with some success in the management of bulimia nervosa.
PharmacodynamicsPhenelzine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects. Response to therapy generally occurs 2 - 4 weeks following onset though some patients may not experience symptom relief for up to 8 weeks.
Mechanism of actionAlthough the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron.
AbsorptionReadily absorbed after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated.

Route of eliminationNARDIL ® is extensively metabolized, primarily by oxidation via monoamine oxidase.
Half life1.2-11.6 hours following single dose administration. Multiple-dose pharmacokinetics have not been studied.
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. Hypertensive crisis may occur with the ingestion of tyramine-rich foods such as cured meats, poultry or fish, aged cheeses, concentrated soy products, tap beer and wine, yeast extracts, broad bean pods and fava beans and sauerkraut.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9926
Blood Brain Barrier+0.9405
Caco-2 permeable+0.6863
P-glycoprotein substrateNon-substrate0.6728
P-glycoprotein inhibitor INon-inhibitor0.9439
P-glycoprotein inhibitor IINon-inhibitor0.9767
Renal organic cation transporterNon-inhibitor0.6026
CYP450 2C9 substrateNon-substrate0.9166
CYP450 2D6 substrateNon-substrate0.5788
CYP450 3A4 substrateNon-substrate0.8056
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8945
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testAMES toxic0.6836
CarcinogenicityCarcinogens 0.699
BiodegradationNot ready biodegradable0.8301
Rat acute toxicity2.6507 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7405
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg
Tablet, film coatedoral15 mg/1
Tabletoral15 mg/1
Prices
Unit descriptionCostUnit
Phenelzine sulfate powder51.0USD g
Nardil 15 mg tablet0.95USD tablet
Nardil 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point74 °C at 1.00E-01 mm HgPhysProp
water solubility29.1 g/LNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.1 mg/mLALOGPS
logP1.2ALOGPS
logP1.2ChemAxon
logS-1.1ALOGPS
pKa (Strongest Basic)5.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.26 m3·mol-1ChemAxon
Polarizability15.8 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-z200000000-833e467e14c48ae4f6b3View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. Pubmed
  2. Sowa BN, Holt A, Todd KG, Baker GB: Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol. 2004 Sep;42(9):851-7. Pubmed
External Links
ATC CodesN06AF03
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelDownload (38.9 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcarbosePhenelzine may increase the hypoglycemic activities of Acarbose.
AcebutololPhenelzine may increase the orthostatic hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acepromazine.
AcetazolamidePhenelzine may increase the orthostatic hypotensive activities of Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Acetophenazine.
AclidiniumAclidinium may increase the anticholinergic activities of Phenelzine.
AlbiglutidePhenelzine may increase the hypoglycemic activities of Albiglutide.
AlfentanilAlfentanil may increase the serotonergic activities of Phenelzine.
AlfuzosinPhenelzine may increase the orthostatic hypotensive activities of Alfuzosin.
AliskirenPhenelzine may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Phenelzine.
AlogliptinPhenelzine may increase the hypoglycemic activities of Alogliptin.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Phenelzine.
AmantadinePhenelzine may increase the orthostatic hypotensive activities of Amantadine.
AmiloridePhenelzine may increase the orthostatic hypotensive activities of Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amisulpride.
AmitriptylinePhenelzine may increase the serotonergic activities of Amitriptyline.
AmlodipinePhenelzine may increase the hypotensive activities of Amlodipine.
AmoxapinePhenelzine may increase the serotonergic activities of Amoxapine.
AmphetaminePhenelzine may increase the hypertensive activities of Amphetamine.
AnagrelidePhenelzine may increase the orthostatic hypotensive activities of Anagrelide.
ApomorphinePhenelzine may increase the orthostatic hypotensive activities of Apomorphine.
ApraclonidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Apraclonidine.
ArformoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Arformoterol.
AripiprazoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Aripiprazole.
ArticainePhenelzine may increase the hypertensive activities of Articaine.
AsenapinePhenelzine may increase the orthostatic hypotensive activities of Asenapine.
AtenololPhenelzine may increase the orthostatic hypotensive activities of Atenolol.
AtomoxetinePhenelzine may increase the central neurotoxic activities of Atomoxetine.
AtropinePhenelzine may increase the hypertensive activities of Atropine.
Azilsartan medoxomilPhenelzine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.
BenazeprilPhenelzine may increase the orthostatic hypotensive activities of Benazepril.
BendroflumethiazidePhenelzine may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenzphetaminePhenelzine may increase the hypertensive activities of Benzphetamine.
BenzquinamideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Benzquinamide.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Phenelzine.
BetaxololPhenelzine may increase the orthostatic hypotensive activities of Betaxolol.
BezafibrateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bezafibrate.
BisoprololPhenelzine may increase the orthostatic hypotensive activities of Bisoprolol.
Botulinum Toxin Type APhenelzine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BPhenelzine may increase the anticholinergic activities of Botulinum Toxin Type B.
BretyliumPhenelzine may increase the orthostatic hypotensive activities of Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brimonidine.
BromocriptinePhenelzine may increase the orthostatic hypotensive activities of Bromocriptine.
BumetanidePhenelzine may increase the orthostatic hypotensive activities of Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine.
BupropionPhenelzine may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Phenelzine.
CabergolinePhenelzine may increase the orthostatic hypotensive activities of Cabergoline.
CanagliflozinPhenelzine may increase the hypoglycemic activities of Canagliflozin.
CandesartanPhenelzine may increase the orthostatic hypotensive activities of Candesartan.
CaptoprilPhenelzine may increase the orthostatic hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenelzine.
CarbidopaThe risk or severity of adverse effects can be increased when Carbidopa is combined with Phenelzine.
CarphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Carphenazine.
CarteololPhenelzine may increase the orthostatic hypotensive activities of Carteolol.
CarvedilolPhenelzine may increase the orthostatic hypotensive activities of Carvedilol.
CathinonePhenelzine may increase the hypertensive activities of Cathinone.
ChlordiazepoxidePhenelzine may increase the orthostatic hypotensive activities of Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlormezanone.
ChlorothiazidePhenelzine may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorpromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorpromazine.
ChlorpropamidePhenelzine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorprothixene.
ChlorthalidonePhenelzine may increase the orthostatic hypotensive activities of Chlorthalidone.
CilazaprilPhenelzine may increase the orthostatic hypotensive activities of Cilazapril.
Cimetropium BromidePhenelzine may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramPhenelzine may increase the serotonergic activities of Citalopram.
ClemastinePhenelzine may increase the anticholinergic activities of Clemastine.
ClevidipinePhenelzine may increase the hypotensive activities of Clevidipine.
ClidiniumPhenelzine may increase the orthostatic hypotensive activities of Clidinium.
ClomipraminePhenelzine may increase the serotonergic activities of Clomipramine.
ClonidinePhenelzine may increase the orthostatic hypotensive activities of Clonidine.
ClorazepatePhenelzine may increase the orthostatic hypotensive activities of Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clozapine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Phenelzine.
CyproheptadinePhenelzine may increase the anticholinergic activities of Cyproheptadine.
DacarbazinePhenelzine may increase the orthostatic hypotensive activities of Dacarbazine.
DapagliflozinPhenelzine may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenelzine.
DesipraminePhenelzine may increase the serotonergic activities of Desipramine.
DesvenlafaxinePhenelzine may increase the serotonergic activities of Desvenlafaxine.
DexmedetomidinePhenelzine may increase the orthostatic hypotensive activities of Dexmedetomidine.
DexmethylphenidatePhenelzine may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetaminePhenelzine may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanPhenelzine may increase the serotonergic activities of Dextromethorphan.
DiazoxidePhenelzine may increase the orthostatic hypotensive activities of Diazoxide.
DiclofenamidePhenelzine may increase the orthostatic hypotensive activities of Diclofenamide.
DiethylpropionPhenelzine may increase the hypertensive activities of Diethylpropion.
DiltiazemPhenelzine may increase the hypotensive activities of Diltiazem.
DisopyramidePhenelzine may increase the hypoglycemic activities of Disopyramide.
DomperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Domperidone.
DoxapramPhenelzine may increase the hypertensive activities of Doxapram.
DoxazosinPhenelzine may increase the orthostatic hypotensive activities of Doxazosin.
DoxepinPhenelzine may increase the serotonergic activities of Doxepin.
DoxylaminePhenelzine may increase the anticholinergic activities of Doxylamine.
DronabinolPhenelzine may increase the orthostatic hypotensive activities of Dronabinol.
DroperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.
DulaglutidePhenelzine may increase the hypoglycemic activities of Dulaglutide.
DuloxetinePhenelzine may increase the serotonergic activities of Duloxetine.
EluxadolinePhenelzine may increase the activities of Eluxadoline.
EmpagliflozinPhenelzine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilPhenelzine may increase the orthostatic hypotensive activities of Enalapril.
EnalaprilatPhenelzine may increase the orthostatic hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Phenelzine.
EphedrinePhenelzine may increase the hypertensive activities of Ephedrine.
EpinephrinePhenelzine may increase the hypertensive activities of Epinephrine.
EplerenonePhenelzine may increase the orthostatic hypotensive activities of Eplerenone.
EprosartanPhenelzine may increase the orthostatic hypotensive activities of Eprosartan.
ErythromycinPhenelzine may increase the hypoglycemic activities of Erythromycin.
EscitalopramPhenelzine may increase the serotonergic activities of Escitalopram.
EsmololPhenelzine may increase the orthostatic hypotensive activities of Esmolol.
Ethacrynic acidPhenelzine may increase the orthostatic hypotensive activities of Ethacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phenelzine.
ExenatidePhenelzine may increase the hypoglycemic activities of Exenatide.
FelodipinePhenelzine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fencamfamine.
FenoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fenoterol.
FentanylFentanyl may increase the serotonergic activities of Phenelzine.
FluoxetinePhenelzine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluticasone Propionate.
FluvoxaminePhenelzine may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Formoterol.
FosinoprilPhenelzine may increase the orthostatic hypotensive activities of Fosinopril.
FurosemidePhenelzine may increase the orthostatic hypotensive activities of Furosemide.
GliclazidePhenelzine may increase the hypoglycemic activities of Gliclazide.
GlimepiridePhenelzine may increase the hypoglycemic activities of Glimepiride.
GlipizidePhenelzine may increase the hypoglycemic activities of Glipizide.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Phenelzine is combined with Glucagon recombinant.
GlyburidePhenelzine may increase the hypoglycemic activities of Glyburide.
GlycopyrrolatePhenelzine may increase the orthostatic hypotensive activities of Glycopyrrolate.
GranisetronGranisetron may increase the serotonergic activities of Phenelzine.
GuanfacinePhenelzine may increase the orthostatic hypotensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.
HydralazinePhenelzine may increase the orthostatic hypotensive activities of Hydralazine.
HydrochlorothiazidePhenelzine may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydromorphone.
IloperidonePhenelzine may increase the orthostatic hypotensive activities of Iloperidone.
ImipraminePhenelzine may increase the serotonergic activities of Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.
IndapamidePhenelzine may increase the orthostatic hypotensive activities of Indapamide.
inhaled insulinPhenelzine may increase the hypoglycemic activities of inhaled insulin.
Insulin AspartPhenelzine may increase the hypoglycemic activities of Insulin Aspart.
Insulin degludecPhenelzine may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirPhenelzine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlarginePhenelzine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisinePhenelzine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin LisproPhenelzine may increase the hypoglycemic activities of Insulin Lispro.
Insulin RegularPhenelzine may increase the hypoglycemic activities of Insulin Regular.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Phenelzine.
IrbesartanPhenelzine may increase the orthostatic hypotensive activities of Irbesartan.
IsocarboxazidPhenelzine may increase the orthostatic hypotensive activities of Isocarboxazid.
IsomethepteneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isometheptene.
IsradipinePhenelzine may increase the hypotensive activities of Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Phenelzine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phenelzine.
LabetalolPhenelzine may increase the orthostatic hypotensive activities of Labetalol.
LanreotidePhenelzine may increase the hypoglycemic activities of Lanreotide.
LevobunololPhenelzine may increase the orthostatic hypotensive activities of Levobunolol.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Phenelzine.
LevomilnacipranPhenelzine may increase the serotonergic activities of Levomilnacipran.
LevonordefrinPhenelzine may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Phenelzine is combined with Linezolid.
LiraglutidePhenelzine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetaminePhenelzine may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilPhenelzine may increase the orthostatic hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lithium.
LosartanPhenelzine may increase the orthostatic hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Loxapine.
LurasidonePhenelzine may increase the orthostatic hypotensive activities of Lurasidone.
MannitolPhenelzine may increase the orthostatic hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenelzine.
MecamylaminePhenelzine may increase the orthostatic hypotensive activities of Mecamylamine.
MecaserminPhenelzine may increase the hypoglycemic activities of Mecasermin.
MepivacainePhenelzine may increase the hypertensive activities of Mepivacaine.
MequitazinePhenelzine may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mesoridazine.
MetforminPhenelzine may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methadone.
MethamphetaminePhenelzine may increase the hypertensive activities of Methamphetamine.
MethazolamidePhenelzine may increase the orthostatic hypotensive activities of Methazolamide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methotrimeprazine.
MethyclothiazidePhenelzine may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methyldopa.
Methylene bluePhenelzine may increase the serotonergic activities of Methylene blue.
MethylphenidatePhenelzine may increase the hypertensive activities of Methylphenidate.
MetipranololPhenelzine may increase the orthostatic hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.
MetolazonePhenelzine may increase the orthostatic hypotensive activities of Metolazone.
MetoprololPhenelzine may increase the orthostatic hypotensive activities of Metoprolol.
MianserinPhenelzine may increase the neurotoxic activities of Mianserin.
MidodrinePhenelzine may increase the hypertensive activities of Midodrine.
MifepristonePhenelzine may increase the hypoglycemic activities of Mifepristone.
MiglitolPhenelzine may increase the hypoglycemic activities of Miglitol.
MilnacipranPhenelzine may increase the serotonergic activities of Milnacipran.
MinoxidilPhenelzine may increase the orthostatic hypotensive activities of Minoxidil.
MirabegronThe risk or severity of adverse effects can be increased when Phenelzine is combined with Mirabegron.
MirtazapinePhenelzine may increase the central neurotoxic activities of Mirtazapine.
MitotanePhenelzine may increase the orthostatic hypotensive activities of Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moclobemide.
MoexiprilPhenelzine may increase the orthostatic hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Morphine.
MoxonidinePhenelzine may increase the hypotensive activities of Moxonidine.
NadololPhenelzine may increase the orthostatic hypotensive activities of Nadolol.
NaphazolinePhenelzine may increase the hypertensive activities of Naphazoline.
NateglinidePhenelzine may increase the hypoglycemic activities of Nateglinide.
NebivololPhenelzine may increase the orthostatic hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nefazodone.
NicardipinePhenelzine may increase the orthostatic hypotensive activities of Nicardipine.
NifedipinePhenelzine may increase the orthostatic hypotensive activities of Nifedipine.
NimodipinePhenelzine may increase the hypotensive activities of Nimodipine.
NisoldipinePhenelzine may increase the hypotensive activities of Nisoldipine.
NitroprussidePhenelzine may increase the hypotensive activities of Nitroprusside.
NorepinephrinePhenelzine may increase the hypertensive activities of Norepinephrine.
NortriptylinePhenelzine may increase the serotonergic activities of Nortriptyline.
OctreotidePhenelzine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine.
OlmesartanPhenelzine may increase the orthostatic hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Olodaterol.
OndansetronThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Orciprenaline.
OxycodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Oxycodone.
OxymetazolinePhenelzine may increase the hypertensive activities of Oxymetazoline.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenelzine.
PaliperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.
ParoxetinePhenelzine may increase the serotonergic activities of Paroxetine.
PasireotidePhenelzine may increase the hypoglycemic activities of Pasireotide.
PenbutololPhenelzine may increase the orthostatic hypotensive activities of Penbutolol.
PentamidinePhenelzine may increase the hypoglycemic activities of Pentamidine.
PerindoprilPhenelzine may increase the orthostatic hypotensive activities of Perindopril.
PerphenazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perphenazine.
PethidinePhenelzine may increase the serotonergic activities of Pethidine.
PhendimetrazinePhenelzine may increase the hypertensive activities of Phendimetrazine.
PheniraminePhenelzine may increase the hypertensive activities of Pheniramine.
PhenoxybenzaminePhenelzine may increase the orthostatic hypotensive activities of Phenoxybenzamine.
PhenterminePhenelzine may increase the hypertensive activities of Phentermine.
PhentolaminePhenelzine may increase the orthostatic hypotensive activities of Phentolamine.
PhenylephrinePhenelzine may increase the hypertensive activities of Phenylephrine.
PholcodinePholcodine may increase the serotonergic activities of Phenelzine.
PimozideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pimozide.
PindololPhenelzine may increase the orthostatic hypotensive activities of Pindolol.
PioglitazonePhenelzine may increase the hypoglycemic activities of Pioglitazone.
PiperacetazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Piperacetazine.
PirbuterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pirbuterol.
PizotifenPhenelzine may increase the anticholinergic activities of Pizotifen.
Potassium ChloridePhenelzine may increase the ulcerogenic activities of Potassium Chloride.
PramipexolePhenelzine may increase the orthostatic hypotensive activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Phenelzine.
PrazosinPhenelzine may increase the orthostatic hypotensive activities of Prazosin.
ProcarbazinePhenelzine may increase the orthostatic hypotensive activities of Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Phenelzine.
PromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.
PromethazinePhenelzine may increase the orthostatic hypotensive activities of Promethazine.
PropanthelinePhenelzine may increase the orthostatic hypotensive activities of Propantheline.
PropranololPhenelzine may increase the orthostatic hypotensive activities of Propranolol.
PropylhexedrinePhenelzine may increase the hypertensive activities of Propylhexedrine.
ProtriptylinePhenelzine may increase the serotonergic activities of Protriptyline.
PseudoephedrinePhenelzine may increase the hypertensive activities of Pseudoephedrine.
QuetiapineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.
QuinaprilPhenelzine may increase the orthostatic hypotensive activities of Quinapril.
QuininePhenelzine may increase the hypoglycemic activities of Quinine.
RacepinephrinePhenelzine may increase the hypertensive activities of Racepinephrine.
RamiprilPhenelzine may increase the orthostatic hypotensive activities of Ramipril.
RamosetronPhenelzine may increase the activities of Ramosetron.
RasagilinePhenelzine may increase the orthostatic hypotensive activities of Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Phenelzine.
RemoxiprideThe risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride.
RepaglinidePhenelzine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Reserpine.
RimantadinePhenelzine may increase the orthostatic hypotensive activities of Rimantadine.
RisperidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Risperidone.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Phenelzine.
RopinirolePhenelzine may increase the orthostatic hypotensive activities of Ropinirole.
RosiglitazonePhenelzine may increase the hypoglycemic activities of Rosiglitazone.
RotigotinePhenelzine may increase the orthostatic hypotensive activities of Rotigotine.
SalbutamolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salmeterol.
SaxagliptinPhenelzine may increase the hypoglycemic activities of Saxagliptin.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Phenelzine.
SelegilinePhenelzine may increase the orthostatic hypotensive activities of Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sertindole.
SertralinePhenelzine may increase the serotonergic activities of Sertraline.
SilodosinPhenelzine may increase the orthostatic hypotensive activities of Silodosin.
SitagliptinPhenelzine may increase the hypoglycemic activities of Sitagliptin.
SotalolPhenelzine may increase the orthostatic hypotensive activities of Sotalol.
SpironolactonePhenelzine may increase the orthostatic hypotensive activities of Spironolactone.
SuccinylcholinePhenelzine may increase the neuromuscular blocking activities of Succinylcholine.
SufentanilSufentanil may increase the serotonergic activities of Phenelzine.
SulfadiazinePhenelzine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazolePhenelzine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazolePhenelzine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Phenelzine.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Phenelzine.
SunitinibPhenelzine may increase the hypoglycemic activities of Sunitinib.
TacrineThe therapeutic efficacy of Phenelzine can be decreased when used in combination with Tacrine.
TamsulosinPhenelzine may increase the orthostatic hypotensive activities of Tamsulosin.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Phenelzine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Phenelzine.
TelmisartanPhenelzine may increase the orthostatic hypotensive activities of Telmisartan.
TerazosinPhenelzine may increase the orthostatic hypotensive activities of Terazosin.
TerbutalineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenelzine.
TetryzolinePhenelzine may increase the hypertensive activities of Tetryzoline.
ThioridazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Phenelzine.
TimololPhenelzine may increase the orthostatic hypotensive activities of Timolol.
TiotropiumPhenelzine may increase the anticholinergic activities of Tiotropium.
TizanidinePhenelzine may increase the orthostatic hypotensive activities of Tizanidine.
TolazamidePhenelzine may increase the hypoglycemic activities of Tolazamide.
TolbutamidePhenelzine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Phenelzine.
TopiramateThe risk or severity of adverse effects can be increased when Phenelzine is combined with Topiramate.
TorasemidePhenelzine may increase the orthostatic hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Phenelzine.
TrandolaprilPhenelzine may increase the orthostatic hypotensive activities of Trandolapril.
TranylcyprominePhenelzine may increase the orthostatic hypotensive activities of Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trazodone.
TriamterenePhenelzine may increase the orthostatic hypotensive activities of Triamterene.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Phenelzine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Triflupromazine.
TrimethoprimPhenelzine may increase the hypoglycemic activities of Trimethoprim.
TrimipraminePhenelzine may increase the serotonergic activities of Trimipramine.
TriprolidinePhenelzine may increase the hypertensive activities of Triprolidine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Phenelzine.
ValsartanPhenelzine may increase the orthostatic hypotensive activities of Valsartan.
VenlafaxinePhenelzine may increase the serotonergic activities of Venlafaxine.
VerapamilPhenelzine may increase the hypotensive activities of Verapamil.
VilanterolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Vilanterol.
VilazodonePhenelzine may increase the serotonergic activities of Vilazodone.
VinblastinePhenelzine may increase the orthostatic hypotensive activities of Vinblastine.
VincristinePhenelzine may increase the orthostatic hypotensive activities of Vincristine.
VortioxetinePhenelzine may increase the serotonergic activities of Vortioxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Phenelzine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.
Food Interactions
  • Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid St.John's Wort.
  • Take without regard to meals.

Targets

1. Amine oxidase [flavin-containing] A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] A P21397 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. Epub 2009 Feb 6. Pubmed
  3. Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. Epub 2008 Aug 13. Pubmed
  4. Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. Pubmed
  5. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. Pubmed
  6. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. Pubmed
  7. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. Pubmed
  8. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. Pubmed
  9. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. Pubmed

2. Amine oxidase [flavin-containing] B

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] B P27338 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. Epub 2009 Feb 6. Pubmed
  3. Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. Epub 2008 Aug 13. Pubmed
  4. Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8. Pubmed
  5. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. Pubmed
  6. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. Pubmed
  7. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40. Pubmed
  8. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68. Pubmed

3. Membrane primary amine oxidase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Membrane primary amine oxidase Q16853 Details

References:

  1. Tipnis UR, Tao M, Boor PJ: Purification and characterization of semicarbazide-sensitive amine oxidase from porcine aorta. Cell Mol Biol (Noisy-le-grand). 1992 Aug-Sep;38(5-6):575-84. Pubmed
  2. Kumar D, Trent MB, Boor PJ: Allylamine and beta-aminopropionitrile induced aortic medial necrosis: mechanisms of synergism. Toxicology. 1998 Feb 6;125(2-3):107-15. Pubmed
  3. Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. Epub 2009 Feb 6. Pubmed
  4. Biasi D, Caramaschi P, Pacor ML, Carletto A, Melchiori S, Manzo T, Bambara LM: [Multiple osseous avascular necrosis in a patient with systemic lupus erythematosus with antiphospholipid antibody positivity] Recenti Prog Med. 1995 Nov;86(11):449-50. Pubmed
  5. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. Pubmed
  6. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M: Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol. 1996 Jul 26;52(2):187-95. Pubmed

4. 4-aminobutyrate aminotransferase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
4-aminobutyrate aminotransferase, mitochondrial P80404 Details

References:

  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. Pubmed
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. Pubmed
  3. McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22. Pubmed
  4. McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF: Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol. 1992 Jun 9;43(11):2486-9. Pubmed
  5. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. Pubmed
  6. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. Pubmed
  7. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. Pubmed

5. Alanine aminotransferase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Alanine aminotransferase 1 P24298 Details

References:

  1. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. Pubmed
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. Pubmed
  3. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. Pubmed

6. Alanine aminotransferase 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Alanine aminotransferase 2 Q8TD30 Details

References:

  1. Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s. Pubmed
  2. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39. Pubmed
  3. McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82. Pubmed

7. Glutamic acid decarboxylase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Glutamic acid decarboxylase Q9UGI5 Details

References:

  1. McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22. Pubmed

Enzymes

1. Amine oxidase [flavin-containing] A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] A P21397 Details

References:

  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. Pubmed

2. Amine oxidase [flavin-containing] B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] B P27338 Details

References:

  1. MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Cytochrome P450 2E1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Runge-Morris M, Feng Y, Zangar RC, Novak RF: Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos. 1996 Jul;24(7):734-7. Pubmed

4. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 3A43

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A43 Q9HB55 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. Cytochrome P450 3A7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 15, 2016 17:38